Hashimoto's thyroiditis is the most common autoimmune thyroid disorder, in which the immune system mistakenly attacks the thyroid gland, causing chronic inflammation, progressive thyroid tissue destruction, and eventually hypothyroidism. Treatment is typically thyroid hormone replacement (levothyroxine) — it addresses the hormone deficiency but does not halt the autoimmune destruction. MSC therapy offers a disease-modifying approach targeting the immune dysregulation itself.
How MSCs Target Hashimoto's
Suppressing Pro-Inflammatory Cytokines
The thyroid destruction in Hashimoto's is driven by TNF-α and IL-6, which sustain the inflammatory attack on thyroid follicular cells. MSCs reduce the production of these inflammatory molecules, helping slow disease progression and minimize further thyroid damage.
Increasing Regulatory T-Cells
Tregs are immune cells that prevent autoimmunity by ensuring the immune system doesn't attack the body's own tissues. In Hashimoto's, Treg function is impaired. MSCs promote Treg expansion, calming the immune system and reducing the attack on the thyroid gland.
Reducing Thyroid Peroxidase (TPO) Antibodies
TPO antibodies are the hallmark laboratory marker of Hashimoto's and directly contribute to thyroid damage. In pre-clinical models and early clinical reports, MSC administration is associated with reductions in TPO antibody titers, suggesting the autoimmune process is being modulated — not just its downstream hormonal consequences.
What to Expect
MSC therapy for Hashimoto's is not a replacement for levothyroxine where it is already clinically indicated. The goal is to reduce the rate of thyroid destruction, lower antibody titers, and potentially reduce symptoms like fatigue, cognitive fog, and joint pain that persist even with adequate hormone replacement. TPO antibody response is monitored at 3, 6, and 12 months post-treatment.